PepGen (PEPG) EBT (2021 - 2026)
PepGen (PEPG) posted EBT of -$17.7 million for Q1 2026, up 2.97% sequentially from -$18.3 million in Q4 2025, and up 41.24% YoY from -$12.6 million in Q1 2025.
PepGen (PEPG) EBT (2021 - 2026) Analysis & Trends
PepGen has reported EBT for 6 years, with the latest figure at -$17.7 million in Q1 2026.
- Quarterly EBT rose 41.24% year-over-year to -$17.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$77.2 million (up 24.93% YoY) and the FY2025 annual result came in at -$89.6 million, up 1.09% from the prior year.
- EBT grew to -$17.7 million in Q1 2026 per PEPG's latest filing, from -$18.3 million in the prior quarter.
- Over five years, EBT peaked at -$13.8 million in Q1 2022 and troughed at -$47.0 million in Q4 2022.
- A 5-year average of -$22.0 million and a median of -$19.4 million in 2023 frame the typical range for EBT.
- The sharpest annual moves came in 2022 and 2023: EBT plunged 4784.01% in 2022, then jumped 58.71% in 2023.
- Over 5 years, EBT stood at -$47.0 million in 2022, then surged by 58.71% to -$19.4 million in 2023, then decreased by 17.7% to -$22.9 million in 2024, then grew by 19.98% to -$18.3 million in 2025, then climbed by 2.97% to -$17.7 million in 2026.
- According to Business Quant data, EBT over the past three periods registered -$17.7 million, -$18.3 million, and -$18.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | PepGen | 207.09 Mn | 207.09 Mn | - | -17.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -17.80 Mn |
| Mar 31, 2026 | -17.75 Mn |
| Dec 31, 2025 | -18.29 Mn |
| Sep 30, 2025 | -18.03 Mn |
| Jun 30, 2025 | -23.09 Mn |
| Mar 31, 2025 | -30.20 Mn |
| Dec 31, 2024 | -22.86 Mn |
| Sep 30, 2024 | -21.38 Mn |
| Jun 30, 2024 | -28.34 Mn |
| Mar 31, 2024 | -18.02 Mn |
| Dec 31, 2023 | -19.42 Mn |
| Sep 30, 2023 | -23.29 Mn |
| Jun 30, 2023 | -19.52 Mn |
| Mar 31, 2023 | -16.32 Mn |
| Dec 31, 2022 | -47.03 Mn |
| Sep 30, 2022 | -18.61 Mn |
| Jun 30, 2022 | -17.32 Mn |
| Mar 31, 2022 | -13.83 Mn |
| Dec 31, 2021 | -963,000.00 |
| Sep 30, 2021 | -8.11 Mn |